Gilead's Harvoni wins Japanese nod
This article was originally published in Scrip
Japanese authorities have approved Gilead's once-daily single pill, Harvoni (ledipasvir plus sofosbuvir), for hepatitis C genotype 1 patients. Also approved for genotype 1 patients in Japan are Merck & Co's Vanihep (vaniprevir) and Bristol-Myers Squibb's all-oral, interferon- and ribavirin-free two-pill regimen Daklinza (daclatasvir) and Sunvepra (asunaprevir), as well as Janssen Pharmaceutical's Sovriad (simeprevir). The news comes not long after Gilead's Sovalidi was granted a price well below that set in the US for genotype 2 patients. The Harvoni approval was backed by data from the Phase III clinical trial GS-US-337-0113 with 318 treatment-naïve and treatment-experienced Japanese patients with genotype 1 HCV infection randomized to ledipasvir plus sofosbuvir or ledipasvir plus sofosbuvir plus ribavirin.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.